<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">29896521</PMID><DateRevised><Year>2020</Year><Month>09</Month><Day>30</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Print">2352-3409</ISSN><JournalIssue CitedMedium="Print"><Volume>18</Volume><PubDate><Year>2018</Year><Month>Jun</Month></PubDate></JournalIssue><Title>Data in brief</Title><ISOAbbreviation>Data Brief</ISOAbbreviation></Journal><ArticleTitle>Relationship between intraocular pressure lowering effect and chemical structure of imidazo[1,2-a]benzimidazole and pyrimido[1,2-a]benzimidazole derivatives.</ArticleTitle><Pagination><StartPage>340</StartPage><EndPage>347</EndPage><MedlinePgn>340-347</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.dib.2018.02.067</ELocationID><Abstract><AbstractText>This article contains data that relate to the study carried out in the work of Marcus et al. (2018) [1]. Data represent an information about pharmacophore analysis of imidazo[1,2-a]benzimidazole and pyrimido[1,2-a]benzimidazole derivatives and results of construction of the relationship between intraocular pressure (IOP) lowering activity and hypotensive activity of imidazo[1,2-a]benzimidazole and pyrimido[1,2-a]benzimidazole derivatives using a multilayer perceptron artificial neural network. In particular, they include the ones listed in this article: 1) table of all pharmacophores of imidazo[1,2-a]benzimidazole and pyrimido[1,2-a]benzimidazole derivatives that showed IOP lowering activity; 2) table of all pharmacophores of the compounds that showed absence of IOP lowering activity; 3) table of initial data for artificial neural network analysis of relationship between IOP activity and hypotensive activity of this chemical series; 4) graphical representation of the best neural network model of this dependence; 5) original txt-file of results of pharmacophore analysis; 6) xls-file of initial data for neural network modeling; 7) original stw-file of results of neural network modeling; 8) original xml-file of the best neural network model of dependence between IOP lowering activity and hypotensive activity of these azole derivatives. The data may be useful for researchers interested in designing new drug substances and will contribute to understanding of the mechanisms of IOP lowering activity.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Vassiliev</LastName><ForeName>Pavel</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Volgograd State Medical University, Research Institute of Pharmacology, Volgograd, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Iezhitsa</LastName><ForeName>Igor</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Volgograd State Medical University, Research Institute of Pharmacology, Volgograd, Russia.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Centre for Neuroscience Research, Faculty of Medicine, Universiti Teknologi MARA, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Agarwal</LastName><ForeName>Renu</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience Research, Faculty of Medicine, Universiti Teknologi MARA, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcus</LastName><ForeName>Adrian Julian</ForeName><Initials>AJ</Initials><AffiliationInfo><Affiliation>Centre for Neuroscience Research, Faculty of Medicine, Universiti Teknologi MARA, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Spasov</LastName><ForeName>Alexander</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Volgograd State Medical University, Research Institute of Pharmacology, Volgograd, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhukovskaya</LastName><ForeName>Olga</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Southern Federal University, Research Institute of Physical and Organic Chemistry, Rostov-on-Don, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Anisimova</LastName><ForeName>Vera</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Southern Federal University, Research Institute of Physical and Organic Chemistry, Rostov-on-Don, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2018</Year><Month>03</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Data Brief</MedlineTA><NlmUniqueID>101654995</NlmUniqueID><ISSNLinking>2352-3409</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Artificial neural network modeling</Keyword><Keyword MajorTopicYN="N">Hypotensive activity;</Keyword><Keyword MajorTopicYN="N">Imidazo[1,2-a]benzimidazoles</Keyword><Keyword MajorTopicYN="N">In silico drug design</Keyword><Keyword MajorTopicYN="N">Intraocular pressure lowering activity</Keyword><Keyword MajorTopicYN="N">Intraocular pressure;</Keyword><Keyword MajorTopicYN="N">Pharmacophore analysis</Keyword><Keyword MajorTopicYN="N">Pyrimido[1,2-a]benzimidazoles</Keyword><Keyword MajorTopicYN="N">QSAR</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2017</Year><Month>12</Month><Day>27</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2018</Year><Month>2</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2018</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2018</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2018</Year><Month>6</Month><Day>14</Day><Hour>6</Hour><Minute>1</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2018</Year><Month>3</Month><Day>6</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">29896521</ArticleId><ArticleId IdType="pmc">PMC5995800</ArticleId><ArticleId IdType="doi">10.1016/j.dib.2018.02.067</ArticleId><ArticleId IdType="pii">S2352-3409(18)30187-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>A.J. Marcus, I. Iezhitsa, R. Agarwal, P. Vassiliev, A. Spasov, O. Zhukovskaya, V. Anisimova, B.B. Johari and N.M. Ismail, Intraocular pressure lowering effect and structure-activity relationship of imidazo[1,2-a]benzimidazole and pyrimido[1,2-a]benzimidazole compounds in ocular normotensive rats: insight on possible link with hypotensive activity. Eur. J. Pharm. Sci. 114, 2018, 245, 10.1016/j.ejps.2017.12.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ejps.2017.12.015</ArticleId><ArticleId IdType="pubmed">29274441</ArticleId></ArticleIdList></Reference><Reference><Citation>Spasov A.A., Yozhitsa I.N., Bugaeva L.I., Anisimova V.A. Benzimidazole derivatives: spectrum of pharmacological activity and toxicological properties (a review) Pharm. Chem. J. 1999;33(5):232&#x2013;243.</Citation></Reference><Reference><Citation>Spasov A.A., Smirnova L.A., Iezhitsa I.N., Sergeeva S.A., Ozerov A.A. Pharmacokinetics of benzimidazole derivatives. Vopr. Med. Khim. 2002;48(3):233&#x2013;258.</Citation><ArticleIdList><ArticleId IdType="pubmed">12243082</ArticleId></ArticleIdList></Reference><Reference><Citation>Anisimova V.A., Spasov A.A., Kosolapov V.A., Kucheryavenko A.F., Ostrovskii O.V., Larionov N.P., Libinzon R.E. Synthesis and pharmacological activity of 2-methoxyphenyl-substituted 9-dialkylaminoethylimidazo[1,2-a]benzimidazoles. Pharm. Chem. J. 2005;39(9):476&#x2013;482.</Citation></Reference><Reference><Citation>Anisimova V.A., Kuz'menko T.A., Spasov A.A., Bocharova I.A., Orobinskaya T.A. Synthesis and study of the hypotensive and antiarrhythmic activity of 2,9-disubstituted 3-alkoxycarbonylimidazo[1,2-a]benzimidazoles. Pharm. Chem. J. 1999;33(7):361&#x2013;365.</Citation></Reference><Reference><Citation>Kovalev G.V., Spasov A.A., Bakumov P.A., Reshetov M.E., Anisimova V.A., Kuz'menko T.A., Strokin Yu.V., Dianov V.M. Influence of condensed benzimidazole derivatives on gastric secretion. Khimiko-Farmatsevticheskii Zh. 1990;24(2):127.</Citation></Reference><Reference><Citation>Anisimova V.A., Spasov A.A., Ostrovskii O.V., Dudchenko G.P., Kosolapov V.A., Kucheryavenko A.F., Larionov N.P., Kovalev S.G. Synthesis and pharmacological activity of 3-aroyl- and 3-hetaroylimidazo[1,2-a]benzimidazoles. Pharm. Chem. J. 2002;36(12):637.</Citation></Reference><Reference><Citation>Anisimova V.A., Osipova M.M., Spasov A.A., Turchaeva A.F., Dudchenko G.P., Larionov N.P., Kovalev S.G. Synthesis and pharmacological activity of 1-N- and 10-N-substituted 1(10),2,3,4-tetrahydropyrimido-[1,2-a]benzimidazoles. Pharm. Chem. J. 2002;36(9):468.</Citation></Reference><Reference><Citation>Spasov A.A., Larionov N.P., Sibiryakova T.B., Verovskii V.E., Anisimova V.A., Kovalev S.G., Baldenkov G.N., Men'shikov M.Yu, Kuz'menko T.A., Kuz'menko V.V. Relationship between spasmolytic and gastroprotector properties of benzimidazole derivatives and their anticalmodulinactivity. Khimiko-Farmatsevticheskii Zh. 1998;32(10):22.</Citation></Reference><Reference><Citation>Anisimova V.A., Spasov A.A., Kosolapov V.A., Kucheryavenko A.F., Ostrovskii O.V., Larionov N.P., Libinzon R.E. Synthesis and pharmacological activity of 2-methoxyphenyl-and 2-oxyphenyl-substituted 1-dialkylaminoalkylimidazo[1,2-a]-benzimidazoles. Pharm. Chem. J. 2005;39(11):579.</Citation></Reference><Reference><Citation>V.A. Anisimova, M.V. Levchenko, T.B. Korochina, A.A. Spasov, S.G. Kovalev, G.P. Dudchenko, Patent EP 571253 A1 19931124, Eur. Pat. Appl, 1993, https://register.epo.org/application?number=EP93401239&amp;tab=main (accessed 14.03.18).</Citation></Reference><Reference><Citation>Spasov A.A., Chernikov M.V., Vassiliev P.M. Izd-vo VolgGMU; Volgograd: 2007. Histamine Receptors (Molecular Biological and Pharmacological Aspects) p. 152. (Russian)</Citation></Reference><Reference><Citation>Petrov V.I., Medvedev O.S., Solomin M.Y., Murashev A.N. Guidelines for evaluation of antihypertensive activity of pharmacological substances. In: Khabriev R.W., editor. Guidelines on Experimental (Preclinical) Study of New Pharmacological Substances. 2nd edition. JSC Publishing house &#x201c;Meditsina&#x201d; (Medicine); Moscow: 2005. pp. 444&#x2013;452.</Citation></Reference><Reference><Citation>P.M. Vassiliev, A.N. Kochetkov, IT Microcosm. State Registration Certificate for software program 2011618547 (Russian)31 Oct 2011, 2011.</Citation></Reference><Reference><Citation>Statistica 6.0, StatSoft, Inc., 2006. &#x2329;http://www.statsoft.com/&#x232a;.</Citation></Reference><Reference><Citation>Vassiliev P., Spasov A., Kosolapov V., Kucheryavenko A., Gurova N., Anisimova V. Consensus Drug Design Using IT Microcosm. In: Gorb L., Kuz'min V., Muratov E., editors. Vol. 17. Springer; Dordrecht: 2014. (Application of Computational Techniques in Pharmacy and Medicine. Challenges and Advances in Computational Chemistry and Physics).</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>